仑伐替尼联合TACE对不可切除肝细胞癌患者肿瘤标志物、凋亡分子和血清ST6GAL1、ANG-2、HGF的影响  

Effect of Lenvatinib Combined with TACE on Tumor Markers,Apoptotic Molecules and Serum ST6GAL1,ANG-2 and HGF in Patients with Unresectable Hepatocellular Carcinoma

作　　者：冯旭晶 苏州[2] 税莲 舒泓铭 夏蓉 罗文娟[2] FENG Xu-jing;SU Zhou;SHUI Lian;SHU Hong-ming;XIA Rong';LUO Wen-juan(Clinical Medicine Department of Chuanbei Medical College,Nanchong,Sichuan,637000,China;Department of Oncology,The Second Affiliated Hospital of North Sichuan Medical College/Sichuan Mianyang 404 Hospital,Mianyang,Sichuan,621000,China)

机构地区：[1]川北医学院临床医学系,四川南充637000 [2]川北医学院附属第二医院/四川绵阳四〇四医院肿瘤科,四川绵阳621000

出　　处：《现代生物医学进展》2024年第4期764-767,783,共5页Progress in Modern Biomedicine

基　　金：四川省抗癌协会临床科研项目(齐鲁)(XH2022-113)。

摘　　要：目的:探讨仑伐替尼联合肝动脉化疗栓塞术(TACE)对不可切除肝细胞癌患者肿瘤标志物、凋亡分子和血清唾液酸转移酶1(ST6Gal1)、血管生成素-2(ANG-2)、肝细胞生长因子(HGF)的影响。方法:采用随机数字表法将四川绵阳四0四医院2020年3月~2022年12月期间收治的114例不可切除肝细胞癌患者分为对照组(n=57,TACE治疗)和研究组(n=57,仑伐替尼联合TACE治疗)。对比两组疗效、肿瘤标志物[甲胎蛋白(AFP)、糖类抗原199(CA199)、癌胚抗原(CEA)]、血清凋亡分子[B淋巴细胞瘤-2相关X蛋白(Bax)、B淋巴细胞瘤-2基因(Bcl-2)、存活素(Survivin)、半胱氨酸天冬氨酸蛋白酶-4(Caspase-4)]和血清ST6Gal1、ANG-2、HGF水平,并观察两组治疗期间不良反应发生情况。结果:与对照组相比,研究组的临床总有效率更高(P<0.05)。与对照组相比,研究组治疗后AFP、CA199、CEA水平更低(P<0.05)。与对照组相比,研究组治疗后Bcl-2、Survivin水平更低,Bax、Caspase-4水平更高(P<0.05)。与对照组相比,研究组治疗后ST6Gal1、ANG-2、HGF水平更低(P<0.05)。两组不良反应总发生率组间对比未见差异(P>0.05)。结论:仑伐替尼联合TACE用于不可切除肝细胞癌患者,可提高临床治疗效果,调节肿瘤标志物、凋亡分子和血清ST6Gal1、ANG-2、HGF水平,安全性较好。Objective:To investigate the effects of lenvatinib combined with transcatheter arterial chemoembolization(TACE)on tumor markers,apoptotic molecules,serum sialic acid transferase 1(ST6Gal1),angiopoietin-2(ANG-2)and hepatocyte growth factor(HGF)in patients with unresectable hepatocellular carcinoma.Methods:114 patients with unresectable hepatocellular carcinoma who were admitted to Sichuan Mianyang 404 Hospital from March 2020 to December 2022 were divided into control group(n=57,TACE treatment)and study group(n=57,lenvatinib combine with TACE treatment)by random number table method.The efficacy,tumor markers[alpha-fetoprotein(AFP),carbohydrate antigen 199(CA199),carcinoembryonic antigen(CEA)],serum apoptotic molecules[B-cell lymphoma-2-associated X protein(Bax),B-cell lymphoma-2 gene(Bcl-2),survivin(Survivin),cysteine aspartic protease-4(Caspase-4)]and serum ST6Gal1,ANG-2,HGF levels were compared between two groups,and the incidence of adverse reactions during treatment was observed.Results:Compared with control group,the total clinical effective rate in study group was higher(P<0.05).Compared with control group,the levels of AFP,CA199 and CEA in study group were lower after treatment(P<0.05).Compared with control group,the levels of Bcl-2 and Survivin in study group were lower after treatment,and the levels of Bax and Caspase-4 were higher(P<0.05).Compared with control group,the levels of ST6Gal1,ANG-2 and HGF in study group were lower after treatment(P<0.05).There was no difference in the total incidence of adverse reactions between two groups(P>0.05).Conclusion:Lenvatinib combined with TACE for patients with unresectable hepatocellular carcinoma,which can improve the clinical treatment effect,regulate the levels of tumor markers,apoptotic molecules and serum ST6Gal1,ANG-2 and HGF,with good safety.

关 键 词：仑伐替尼 肝动脉化疗栓塞术 肝细胞癌 肿瘤标志物 凋亡分子 ST6GAL1 ANG-2 HGF 

分 类 号：R735.7[医药卫生—肿瘤]